Revenue (Disaggregation of Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 6,941.6	$ 6,772.8	$ 21,239.6	$ 20,318.5
U.S.
Disaggregation of Revenue [Line Items]
Revenue	4,422.1	3,989.6	13,531.5	11,635.1
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,519.4	2,783.3	7,708.1	8,683.4
Diabetes
Disaggregation of Revenue [Line Items]
Revenue	3,662.6	3,274.1	10,489.0	9,560.6
Diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,488.6	2,143.0	7,057.3	6,284.0
Diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,174.0	1,131.1	3,431.6	3,276.6
Trulicity®
Disaggregation of Revenue [Line Items]
Revenue	1,850.4	1,600.1	5,503.5	4,588.2
Trulicity® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,418.3	1,201.4	4,162.4	3,465.7
Trulicity® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	432.0	398.8	1,341.1	1,122.5
Jardiance
Disaggregation of Revenue [Line Items]
Revenue	573.3	390.4	1,453.7	1,058.9
Jardiance | U.S.
Disaggregation of Revenue [Line Items]
Revenue	350.9	221.2	831.4	566.8
Jardiance | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	222.4	169.2	622.4	492.1
Humalog®
Disaggregation of Revenue [Line Items]
Revenue	447.0	626.7	1,512.3	1,851.3
Humalog® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	248.1	347.3	855.8	1,009.0
Humalog® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	198.8	279.4	656.4	842.3
Humulin®
Disaggregation of Revenue [Line Items]
Revenue	238.2	286.7	785.4	923.8
Humulin® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	169.5	193.4	562.3	633.5
Humulin® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	68.7	93.4	223.1	290.3
Basaglar®
Disaggregation of Revenue [Line Items]
Revenue	193.0	192.8	558.7	650.1
Basaglar® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	124.8	114.7	339.9	423.3
Basaglar® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	68.1	78.1	218.8	226.8
Mounjaro®
Disaggregation of Revenue [Line Items]
Revenue	187.3	0.0	203.2	0.0
Mounjaro® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	97.3	0.0	109.9	0.0
Mounjaro® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	90.0	0.0	93.3	0.0
Other diabetes
Disaggregation of Revenue [Line Items]
Revenue	173.4	177.4	472.2	488.3
Other diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	79.7	65.0	195.6	185.7
Other diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	94.0	112.2	276.5	302.6
Oncology
Disaggregation of Revenue [Line Items]
Revenue	1,293.3	1,406.1	4,015.0	4,332.4
Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	732.7	730.9	2,335.4	2,201.7
Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	560.6	675.3	1,679.6	2,130.7
Verzenio®
Disaggregation of Revenue [Line Items]
Revenue	617.7	335.5	1,675.6	945.8
Verzenio® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	414.8	199.6	1,100.5	582.1
Verzenio® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	202.9	135.9	575.1	363.7
Cyramza®
Disaggregation of Revenue [Line Items]
Revenue	232.1	253.4	693.6	762.5
Cyramza® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	87.5	84.8	259.3	266.3
Cyramza® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	144.6	168.6	434.3	496.3
Erbitux®
Disaggregation of Revenue [Line Items]
Revenue	144.9	134.3	408.3	403.7
Erbitux® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	126.3	114.0	361.0	357.7
Erbitux® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	18.7	20.3	47.4	45.9
Alimta®
Disaggregation of Revenue [Line Items]
Revenue	119.4	457.0	691.1	1,626.6
Alimta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	64.6	297.2	490.5	911.9
Alimta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	54.8	159.8	200.5	714.7
Tyvyt®
Disaggregation of Revenue [Line Items]
Revenue	76.8	125.6	235.8	340.2
Tyvyt® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	0.0	0.0	0.0
Tyvyt® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	76.8	125.6	235.8	340.2
Other oncology
Disaggregation of Revenue [Line Items]
Revenue	102.4	100.3	310.6	253.6
Other oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	39.5	35.3	124.1	83.7
Other oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	62.8	65.1	186.5	169.9
Immunology
Disaggregation of Revenue [Line Items]
Revenue	866.4	1,004.9	2,411.0	2,404.2
Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	516.7	616.2	1,317.3	1,323.3
Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	349.7	388.7	1,093.8	1,080.9
Taltz®
Disaggregation of Revenue [Line Items]
Revenue	679.9	593.1	1,774.2	1,565.4
Taltz® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	493.8	422.2	1,212.6	1,071.6
Taltz® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	186.1	170.9	561.6	493.8
Olumiant®
Disaggregation of Revenue [Line Items]
Revenue	182.9	406.9	624.7	809.1
Olumiant® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	22.9	194.0	104.6	236.5
Olumiant® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	160.0	212.9	520.1	572.6
Other immunology
Disaggregation of Revenue [Line Items]
Revenue	3.6	4.9	12.1	29.7
Other immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	0.0	0.1	15.2
Other immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	3.6	4.9	12.1	14.5
Neuroscience
Disaggregation of Revenue [Line Items]
Revenue	373.2	450.2	1,160.9	1,427.8
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	145.8	144.6	444.0	453.1
Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	227.4	305.5	716.9	974.7
Emgality®
Disaggregation of Revenue [Line Items]
Revenue	168.5	140.0	475.2	415.7
Emgality® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	114.0	99.9	330.8	313.5
Emgality® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	54.6	40.1	144.4	102.2
Zyprexa®
Disaggregation of Revenue [Line Items]
Revenue	81.4	101.7	261.7	292.8
Zyprexa® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	8.0	13.0	26.2	28.3
Zyprexa® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	73.4	88.7	235.5	264.5
Cymbalta®
Disaggregation of Revenue [Line Items]
Revenue	62.7	132.0	219.3	484.3
Cymbalta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	7.8	7.0	25.0	30.3
Cymbalta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	54.9	125.1	194.3	454.0
Other neuroscience
Disaggregation of Revenue [Line Items]
Revenue	60.6	76.5	204.7	235.0
Other neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	16.0	24.7	62.0	81.0
Other neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	44.5	51.6	142.7	154.0
Other
Disaggregation of Revenue [Line Items]
Revenue	746.0	637.7	3,163.7	2,593.5
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	538.3	354.9	2,377.5	1,373.0
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	207.8	282.7	786.2	1,220.5
COVID-19 antibodies
Disaggregation of Revenue [Line Items]
Revenue	386.6	217.1	1,985.5	1,176.2
COVID-19 antibodies | U.S.
Disaggregation of Revenue [Line Items]
Revenue	386.6	215.5	1,970.9	949.5
COVID-19 antibodies | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	1.6	14.7	226.7
Forteo®
Disaggregation of Revenue [Line Items]
Revenue	177.1	200.9	453.0	617.8
Forteo® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	112.7	109.6	261.4	330.1
Forteo® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	64.4	91.3	191.7	287.7
Cialis®
Disaggregation of Revenue [Line Items]
Revenue	115.7	130.9	480.4	538.7
Cialis® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	8.1	(6.5)	25.8	(3.1)
Cialis® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	107.7	137.4	454.7	541.8
Other
Disaggregation of Revenue [Line Items]
Revenue	66.6	88.8	244.8	260.8
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	30.9	36.3	119.4	96.5
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	$ 35.7	$ 52.4	$ 125.1	$ 164.3